NeuroVive strengthens its organization with the recruitment of Cecilia Hofvander as IR and Communications Director
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that it has recruited Cecilia Hofvander as Investor Relations and Communications Director effective from 1 June 2016 in order to strengthen the company’s communication resources.
Cecilia Hofvander joins NeuroVive from Active Biotech AB where she has worked for 15 years, the last eight as Assistant Director Investor Relations & Business Development. She holds a B.Sc in Chemistry and Molecular Biology from Lund University and has completed the Communication Executive Program at the Stockholm School of Economics.
“One of my priorities as NeuroVive’s new CEO is to strengthen our communication team. Cecilia’s communications expertise combined with her experience of the biotech industry will make a valuable contribution,” commented NeuroVive’s CEO Erik Kinnman.
Apart from IR and Communication, Cecilia Hofvander’s broad experience includes business development, financial transactions and international clinical trials with drug candidates.
“NeuroVive has a very promising project portfolio and is in an exciting phase with the results of clinical trials due to be presented over the coming year. I look forward to contributing to the company’s development by communicating NeuroVive’s and its partners’ activities and drug development progress. In my communication work, my priorities are openness and clarity as a means to building long-term relationships with the company’s stakeholders,” commented Cecilia Hofvander.
Christine Tadgell from InVentive Health will coordinate NeuroVive’s external communication in the period until Cecilia Hofvander takes up her position with NeuroVive. The company’s collaboration with IR firm Laika Consulting will also continue.
NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine and a company committed to the discovery and development of highly targeted candidates that preserve mitochondrial integrity and function in areas of significant therapeutic need. NeuroVive’s business approach is driven by value-adding partnerships with mitochondrial research institutions and commercial partners across the globe. NeuroVive’s portfolio consists of two clinical projects in acute kidney injury (AKI) and traumatic brain injury (TBI) with candidates in clinical and preclinical development and two drug discovery platforms. The NeuroSTAT® product has orphan drug status in Europe and in the US for treatment of moderate to severe traumatic brain injury and is currently being evaluated in a study, CHIC. Ciclosporin is being evaluated in an on-going study, CiPRICS, in acute kidney injury during major surgery. NeuroVive’s shares are listed on Nasdaq, Stockholm, Sweden.
For investor relations and media questions, please contact:
Christine Tadgell, NeuroVive, Tel: +46 (0)275 62 21 or email@example.com
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on 08.30 CET on 11 April 2016.
NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The company is listed on NASDAQ OMX Stockholm, Small Cap, under the ticker symbol NVP. The share is also traded on the OTC market in the US. NeuroVive Pharmaceutical (OTC: NEVPF) trades on the OTC Pink Market. Investors can find Real-Time quotes and market information for the company at www.otcmarkets.com/stock/NEVPF/quote